|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:ATCCode
|
J05AP07
|
|
gptkbp:bioavailability
|
34.9% (oral)
|
|
gptkbp:CASNumber
|
937263-43-9
|
|
gptkbp:component
|
Technivie
Viekira Pak
|
|
gptkbp:contraindication
|
severe hepatic impairment
co-administration with strong CYP3A inducers
|
|
gptkbp:drugClass
|
antiviral drug
|
|
gptkbp:drugInteraction
|
gptkb:phenytoin
gptkb:rifampin
gptkb:carbamazepine
gptkb:St._John's_Wort
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:halfLife
|
21-25 hours
|
|
gptkbp:hasInChIKey
|
QXWZOBZKJXOMOE-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C50H67N7O8
|
|
gptkbp:hasSMILES
|
CC(C)COC(=O)C1=CC2=C(C=C1)N=C(N2)NCC3=CC=CC=C3C(=O)N4CCC(CC4)NC(=O)C5=CC=CC=C5C(=O)N6CCC(CC6)NC(=O)C7=CC=CC=C7C(=O)N8CCC(CC8)NC(=O)C9=CC=CC=C9C(=O)N(C)C
|
|
gptkbp:hasUNII
|
6W5C257I5Y
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB08916
|
|
gptkbp:indication
|
chronic hepatitis C infection
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:AbbVie
|
|
gptkbp:mechanismOfAction
|
NS5A inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
893.1 g/mol
|
|
gptkbp:name
|
Ombitasvir
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
N (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB08916
D10568
CHEMBL2108507
46209116
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
fatigue
pruritus
insomnia
asthenia
|
|
gptkbp:status
|
true
|
|
gptkbp:structureType
|
nonstructural protein 5A inhibitor
|
|
gptkbp:synonym
|
ABT-267
Ombitasvirum
|
|
gptkbp:target
|
NS5A protein of HCV
|
|
gptkbp:usedFor
|
treatment of hepatitis C
|
|
gptkbp:bfsParent
|
gptkb:afatinib
gptkb:Afatinib
|
|
gptkbp:bfsLayer
|
7
|